Joseph M.  Busky net worth and biography

Joseph Busky Biography and Net Worth

CFO of QuidelOrtho

Joseph Busky, Chief Financial Officer of QuidelOrtho Corporation, manages global finance and drives value creation to enable growth and long-term value. 

Mr. Busky has more than 30 years of experience in corporate and operational finance for large, global companies across diagnostics, medical devices, telecom, and marketing services. He has worked both for publicly owned companies and within private equity-owned settings. 

Prior to joining Ortho Clinical Diagnostics in July 2020, Mr. Busky served as Chief Financial Officer for Vyaire Medical, Inc., a global medical device company. Before Vyaire, Mr. Busky was Chief Financial Officer of FDH Velocitel, an engineering services company in the telecom space. Previously, he served seven years as Chief Financial Officer of InnerWorkings, Inc., a global marketing services firm with operations in 33 countries, and held corporate and divisional finance roles for a combined 11 years at Siemens Medical Solutions Diagnostics/Dade Behring Holdings, Inc., Bayer Diagnostics and Diagnostic Products Corporation, including serving as Chief Accounting Officer at Dade Behring. 

Mr. Busky holds an MBA with a finance concentration, as well as a BBA in Accounting, from Loyola University in Baltimore. He also has a CPA certification in Maryland.

What is Joseph M. Busky's net worth?

The estimated net worth of Joseph M. Busky is at least $84,065.00 as of February 23rd, 2024. Mr. Busky owns 2,150 shares of QuidelOrtho stock worth more than $84,065 as of November 2nd. This net worth approximation does not reflect any other investments that Mr. Busky may own. Additionally, Mr. Busky receives a salary of $890,630.00 as CFO at QuidelOrtho. Learn More about Joseph M. Busky's net worth.

How old is Joseph M. Busky?

Mr. Busky is currently 56 years old. There are 8 older executives and no younger executives at QuidelOrtho. The oldest executive at QuidelOrtho is Mr. William J. Ferenczy, Point of Care Business Unit Leader, who is 68 years old. Learn More on Joseph M. Busky's age.

What is Joseph M. Busky's salary?

As the CFO of QuidelOrtho Co., Mr. Busky earns $890,630.00 per year. There are 3 executives that earn more than Mr. Busky. The highest earning executive at QuidelOrtho is Ms. Michelle A. Hodges J.D., Senior VP, General Counsel & Corporate Secretary, who commands a salary of $1,800,000.00 per year. Learn More on Joseph M. Busky's salary.

How do I contact Joseph M. Busky?

The corporate mailing address for Mr. Busky and other QuidelOrtho executives is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. QuidelOrtho can also be reached via phone at (800) 874-1517 and via email at [email protected]. Learn More on Joseph M. Busky's contact information.

Has Joseph M. Busky been buying or selling shares of QuidelOrtho?

Joseph M. Busky has not been actively trading shares of QuidelOrtho over the course of the past ninety days. Most recently, on Friday, February 23rd, Joseph M. Busky bought 2,150 shares of QuidelOrtho stock. The stock was acquired at an average cost of $46.35 per share, with a total value of $99,652.50. Following the completion of the transaction, the chief financial officer now directly owns 2,150 shares of the company's stock, valued at $99,652.50. Learn More on Joseph M. Busky's trading history.

Who are QuidelOrtho's active insiders?

QuidelOrtho's insider roster includes Michael Abney, Jr. (SVP), Douglas Bryant (CEO), Joseph Busky (CFO), William Ferenczy (SVP), Werner Kroll (SVP), Edward Michael (Director), Mary Polan (Director), Charles Slacik (Director), Randall Steward (CFO), and Matthew Strobeck (Director). Learn More on QuidelOrtho's active insiders.

Are insiders buying or selling shares of QuidelOrtho?

During the last year, QuidelOrtho insiders bought shares 1 times. They purchased a total of 2,150 shares worth more than $99,652.50. During the last year, insiders at the sold shares 24 times. They sold a total of 2,261,559 shares worth more than $82,700,460.24. The most recent insider tranaction occured on August, 7th when Major Shareholder Carlyle Group Inc. sold 78,180 shares worth more than $3,122,509.20. Insiders at QuidelOrtho own 1.0% of the company. Learn More about insider trades at QuidelOrtho.

Information on this page was last updated on 8/7/2024.

Joseph M. Busky Insider Trading History at QuidelOrtho

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/23/2024Buy2,150$46.35$99,652.502,150View SEC Filing Icon  
See Full Table

Joseph M. Busky Buying and Selling Activity at QuidelOrtho

This chart shows Joseph M Busky's buying and selling at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

QuidelOrtho Company Overview

QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $39.10
Low: $38.45
High: $39.66

50 Day Range

MA: $42.62
Low: $38.05
High: $46.35

2 Week Range

Now: $39.10
Low: $29.74
High: $75.86

Volume

418,992 shs

Average Volume

972,445 shs

Market Capitalization

$2.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.09